Search research articles
Contact Us
Filters
Showing results (201-210 of 235) with videos related to
Page
of 24
Sort By:
Journal of the National Cancer Institute
|
May 1, 1986
Monoclonal antibody against human ovarian tumor-associated antigens
L G Poels, D Peters, Y van Megen, et al.
Seminars in Oncology
|
February 1, 1994
High-dose intensity regimens with epirubicin in ovarian cancer
J B Vermorken, G Bolis, R E van Rijswijk, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists
|
September 28, 2002
Histopathologic features of genetically determined ovarian cancer
P A Shaw, J R McLaughlin, R P Zweemer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2000
Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin
S von Mensdorff-Pouilly, A A Verstraeten, P Kenemans, et al.
Nuclear Medicine Communications
|
July 1, 1991
Kinetics and biodistribution in relation to tumour detection with 111In-labelled OV-TL 3 F(ab')2 in patients with ovarian cancer
L F Massuger, R A Claessens, P Kenemans, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
|
June 27, 2000
Characterization of a new MUC1 monoclonal antibody (VU-2-G7) directed to the glycosylated PDTR sequence of MUC1
K Ryuko, D J Schol, F G Snijdewint, et al.
Histopathology
|
June 26, 2003
Expression of differentiation and proliferation related proteins in epithelium of prophylactically removed ovaries from women with a hereditary female adnexal cancer predisposition
J M J Piek, R H M Verheijen, F H Menko, et al.
Cancer Letters
|
January 15, 1993
The cellular composition in the peritoneal cavity and the cytotoxic function of the peritoneal cells from patients with ovarian cancer; effect of tumor necrosis factor-alpha treatment
C D Richters, C W Burger, A A van de Loosdrecht, et al.
The Journal of Clinical Endocrinology and Metabolism
|
November 14, 1997
Oral 17 beta-estradiol continuously combined with dydrogesterone lowers serum lipoprotein(a) concentrations in healthy postmenopausal women
V Mijatovic, P Kenemans, J C Netelenbos, et al.
Maturitas
|
April 2, 1998
Continuously combined hormone replacement therapy and bone turnover: the influence of dydrogesterone dose, smoking and initial degree of bone turnover
G W de Valk-de Roo, J C Netelenbos, I R Peters-Muller, et al.
Page
of 24
Search research articles
Search
Showing results (201-210 of 235) with videos related to
Sort By:
Page
of 24
Journal of the National Cancer Institute
|
May 1, 1986
Monoclonal antibody against human ovarian tumor-associated antigens
L G Poels, D Peters, Y van Megen, et al.
Seminars in Oncology
|
February 1, 1994
High-dose intensity regimens with epirubicin in ovarian cancer
J B Vermorken, G Bolis, R E van Rijswijk, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists
|
September 28, 2002
Histopathologic features of genetically determined ovarian cancer
P A Shaw, J R McLaughlin, R P Zweemer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2000
Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin
S von Mensdorff-Pouilly, A A Verstraeten, P Kenemans, et al.
Nuclear Medicine Communications
|
July 1, 1991
Kinetics and biodistribution in relation to tumour detection with 111In-labelled OV-TL 3 F(ab')2 in patients with ovarian cancer
L F Massuger, R A Claessens, P Kenemans, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
|
June 27, 2000
Characterization of a new MUC1 monoclonal antibody (VU-2-G7) directed to the glycosylated PDTR sequence of MUC1
K Ryuko, D J Schol, F G Snijdewint, et al.
Histopathology
|
June 26, 2003
Expression of differentiation and proliferation related proteins in epithelium of prophylactically removed ovaries from women with a hereditary female adnexal cancer predisposition
J M J Piek, R H M Verheijen, F H Menko, et al.
Cancer Letters
|
January 15, 1993
The cellular composition in the peritoneal cavity and the cytotoxic function of the peritoneal cells from patients with ovarian cancer; effect of tumor necrosis factor-alpha treatment
C D Richters, C W Burger, A A van de Loosdrecht, et al.
The Journal of Clinical Endocrinology and Metabolism
|
November 14, 1997
Oral 17 beta-estradiol continuously combined with dydrogesterone lowers serum lipoprotein(a) concentrations in healthy postmenopausal women
V Mijatovic, P Kenemans, J C Netelenbos, et al.
Maturitas
|
April 2, 1998
Continuously combined hormone replacement therapy and bone turnover: the influence of dydrogesterone dose, smoking and initial degree of bone turnover
G W de Valk-de Roo, J C Netelenbos, I R Peters-Muller, et al.
Page
of 24